A phase II study of 4SC-202 in combination with checkpoint inhibitors in pre-treated patients with microsatellite-stable gastrointestinal cancers

Trial Profile

A phase II study of 4SC-202 in combination with checkpoint inhibitors in pre-treated patients with microsatellite-stable gastrointestinal cancers

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Avelumab (Primary) ; Domatinostat (Primary)
  • Indications Gastrointestinal cancer
  • Focus Therapeutic Use
  • Acronyms EMERGE
  • Most Recent Events

    • 26 Apr 2018 According to a 4SC media release, the company is expecting to initiate this study in the H1 2018.
    • 21 Mar 2018 According to a 4SC media release, safety data is expected in 2H 2018 and top-line results in H2 2019.
    • 26 Oct 2017 According to a 4SC media release, the company is expecting to initiate this study in the Q1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top